| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 阳景 | 浦银国际证券 | 医药生物 | 59.84% | 25.64% | 0.29% | 100.00% | 4 | 0.00% | 2025-11-06 |
| 2 | 阳景 | 浦银国际证券 | 医药生物 | 59.81% | 26.67% | -5.49% | 100.00% | 4 | 0.00% | 2025-10-30 |
| 3 | 夏禹 | 国联民生 | 医药生物 | 59.77% | 45.53% | 6.82% | 20.00% | 7 | -52.01% | 2025-09-03 |
| 4 | 顾资然 | 中信证券 | 医药生物 | 59.70% | 48.08% | 45.91% | 66.67% | 6 | -1.79% | 2025-08-14 |
| 5 | 韩世通 | 中信证券 | 医药生物 | 59.57% | 50.86% | 40.09% | -2.04% | 6 | -63.25% | 2025-08-25 |
| 6 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 59.46% | 62.99% | 34.13% | 12.50% | 6 | -27.10% | 2025-05-26 |
| 7 | 韩世通 | 中信证券 | 医药生物 | 59.40% | 48.60% | 36.16% | -2.04% | 6 | -63.25% | 2025-09-01 |
| 8 | 顾资然 | 中信证券 | 医药生物 | 59.37% | 57.28% | 50.59% | 66.67% | 7 | -1.79% | 2025-09-16 |
| 9 | 阳景 | 浦银国际证券 | 医药生物 | 59.35% | 74.85% | 26.31% | 100.00% | 3 | 0.00% | 2025-08-04 |
| 10 | 刘浩 | 华创证券 | 医药生物 | 59.24% | 58.96% | 34.73% | 29.41% | 2 | -47.33% | 2025-06-24 |
| 11 | 夏禹 | 国联民生 | 医药生物 | 59.17% | 40.39% | 3.54% | 20.00% | 7 | -52.01% | 2025-09-12 |
| 12 | 韩世通 | 中信证券 | 医药生物 | 59.12% | 48.73% | 30.61% | -2.04% | 6 | -63.25% | 2025-09-05 |
| 13 | 唐寅灏 | 中信证券 | 医药生物 | 59.11% | 33.40% | 5.43% | 85.71% | 13 | -8.47% | 2025-10-10 |
| 14 | 顾资然 | 中信证券 | 医药生物 | 59.10% | 54.29% | 47.44% | 66.67% | 6 | -1.79% | 2025-09-10 |
| 15 | 顾资然 | 中信证券 | 医药生物 | 59.09% | 55.31% | 46.12% | 66.67% | 6 | -1.79% | 2025-09-09 |
| 16 | 仰佳佳 | 申万宏源 | 医药生物 | 58.99% | 46.76% | 22.53% | 23.08% | 3 | -37.64% | 2025-09-03 |
| 17 | 顾资然 | 中信证券 | 医药生物 | 58.97% | 54.93% | 50.19% | 66.67% | 7 | -1.79% | 2025-09-17 |
| 18 | 赵海春 | 国金证券 | 医药生物 | 58.91% | 65.10% | 67.74% | -25.00% | 2 | -61.07% | 2025-07-17 |
| 19 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 58.86% | 63.82% | 39.02% | 12.50% | 6 | -27.10% | 2025-05-22 |
| 20 | 唐寅灏 | 中信证券 | 医药生物 | 58.85% | 24.49% | -12.53% | 85.71% | 9 | -8.47% | 2025-11-03 |